文献速递胸部肿瘤支持与姑息治疗

益生菌对接受PD-1检查点阻断治疗的非小细胞肺癌患者的抗生素依赖性影响

Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade.
PubMed 文献 · Eur J Cancer · 2022-06-30

在293例接受PD-1单药治疗的晚期非小细胞肺癌日本患者中,基于基线皮质类固醇、质子泵抑制剂和抗生素计算的药物评分未能验证其预后价值,但发现益生菌与抗生素存在交互作用(p=0.0510),调整评分后对无进展生存期的诊断能力有所改善。

要点

  • 药物评分将患者分为良好、中等、差三组,中位总生存期分别为19.5、13.4、3.7个月(趋势检验p=0.016)。
  • 益生菌与抗生素交互作用对总生存期p=0.0510,调整评分后三组中位总生存期分别为19.6、13.1、3.7个月。
  • 调整评分对无进展生存期的诊断能力改善(C-index 0.62,95%CI 0.54-0.69)。

核心结论

  • 在独立的日本队列中未能验证药物评分,但显示益生菌可能对抗生素依赖性影响其预后价值。
  • 需要进一步研究伴随用药和益生菌在不同种族队列中的影响。

研究设计与样本

  • 研究为在293例接受PD-1单药治疗的晚期非小细胞肺癌日本患者中评估药物评分预后能力的独立队列研究。

主要发现

  • 良好、中等、差风险组的中位总生存期分别为19.5个月、13.4个月、3.7个月(趋势检验p=0.016),C-index为0.57(95%CI 0.53-0.61)。
  • 对无进展生存期无显著影响(趋势检验p=0.080;C-index 0.55,95%CI 0.52-0.58)。
  • 益生菌与抗生素交互作用对总生存期的p值为0.0510,调整评分后良好、中等、差风险组中位总生存期分别为19.6个月、13.1个月、3.7个月(趋势检验p=0.006;C-index 0.58,95%CI 0.54-0.61)。
  • 调整评分对无进展生存期的诊断能力改善(趋势检验p=0.034;C-index 0.62,95%CI 0.54-0.69)。

关键数值与推荐

  • 药物评分基于基线皮质类固醇、质子泵抑制剂和抗生素计算。
  • 调整评分将同时使用抗生素和益生菌赋为0分。

局限性

  • 在独立的日本队列中未能验证药物评分。
  • 需要进一步研究伴随用药和益生菌在不同种族队列中的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We previously validated in European patients with NSCLC treated with programmed death-1 (PD-1) checkpoint inhibitors the cumulative detrimental effect of concomitant medications. MATERIALS AND METHODS: We evaluated the prognostic ability of a "drug score" computed on the basis of baseline corticosteroids, proton pump inhibitors, and antibiotics, in an independent cohort of Japanese patients with advanced NSCLC treated with PD-1 monotherapy. Subsequently, we assessed the impact of baseline probiotics on the score's diagnostic ability and their interaction with antibiotics in influencing survival. RESULTS: Among the 293 eligible patients, good (19.5 months), intermediate (13.4 months), and poor (3.7 months) risk groups displayed a significantly different overall survival (OS) (log-rank test for trend: p = 0.016), but with a limited diagnostic ability (C-index: 0.57, 95%CI: 0.53-0.61), while no significant impact on progression-free survival (PFS) was reported (log-rank test for trend: p = 0.080; C-index: 0.55, 95%CI: 0.52-0.58). Considering the impact of the probiotics∗antibiotics interaction (p-value 0.0510) on OS, we implemented the drug score by assigning 0 points to concomitant antibiotics and probiotics. With the adapted drug score good, intermediate, and poor risk patients achieved a median OS of 19.6 months, 13.1 months, and 3.7 months, respectively, with a similar diagnostic ability (log-rank test for trend: p = 0.006; C-index: 0.58, 95%CI: 0.54-0.61). However, the diagnostic ability for PFS of the adapted score was improved (log-rank test for trend: p = 0.034; C-index: 0.62, 95%CI: 0.54-0.69). CONCLUSIONS: Although we failed to validate the drug score in this independent Japanese cohort, we showed that probiotics may have an antibiotic-dependent impact on its prognostic value. Further investigation looking at the effect of concomitant medications and probiotics across cohorts of different ethnicities is warranted.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Takada K, Buti S, Bersanelli M, et al. Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade. Eur J Cancer. 2022. PMID: 35780526. doi:10.1016/j.ejca.2022.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。